| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | LQDA Liquidia Corp | Saggar Rajeev | Chief Medical Officer | Sell | 21,142 | $37.43 | $791,345.06 | -10.7% | +5.3% | - | |
| Jan 12, 2026 | LQDA Liquidia Corp | Adair Jason | Chief Business Officer | Sell | 13,548 | $37.43 | $507,101.64 | -6.9% | +5.3% | - | |
| Jan 12, 2026 | LQDA Liquidia Corp | Moomaw Scott | Chief Commercial Officer | Sell | 20,533 | $37.43 | $768,550.19 | -11.7% | +5.3% | - | |
| Jan 9, 2026 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 213 | $40.16 | $8,554.08 | -0.5% | +49.8% | - | |
| Jan 8, 2026 | KNSA Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | Chief Financial Officer | Sell | 12,000 | $41.89 | $502,680.00 | -38.6% | +12.7% | - | |
| Jan 8, 2026 | ALKS Alkermes Plc. | Hopkinson Craig C.54 | EVP R&D, Chief Medical Officer | Sell | 5,000 | $30.00 | $150,005.00 | -7.5% | +17.5% | - | |
| Jan 7, 2026 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 292,148 | $1,103.48 | $322,380,730.46 | - | -16.0% | - | |
| Jan 7, 2026 | PLNH Planet 13 Holdings Inc. | Wren Chris | VP Of Operations | Sell | 30,000 | $0.20 | $6,066.00 | -0.8% | - | - | |
| Jan 7, 2026 | PAHC Phibro Animal Health Corp | Bendheim Jack49 | President And CEO | Sell | 328 | $40.09 | $13,148.77 | -0.8% | +41.2% | - | |
| Jan 6, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 7,715 | $11.09 | $85,596.38 | -0.2% | +39.0% | - | |
| Jan 6, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 7,715 | $11.09 | $85,589.44 | -0.2% | +39.0% | - | |
| Jan 6, 2026 | UTHR United Therapeutics Corp | Causey Christopher59 | Director | Sell | 1,000 | $510.00 | $510,000.00 | -19.3% | +11.3% | - | |
| Jan 6, 2026 | HROW Harrow, Inc. | Opaleye Management Inc.59 | 10% Owner | Sell | 20,000 | $53.35 | $1,066,914.00 | -22.2% | -34.3% | - | |
| Jan 6, 2026 | AMLX Amylyx Pharmaceuticals, Inc. | Frates James M83 | Chief Financial Officer | Sell | 3,326 | $11.11 | $36,953.86 | -1.8% | +39.0% | - | |
| Jan 5, 2026 | UTHR United Therapeutics Corp | Malcolm Jan | Director | Sell | 50 | $495.01 | $24,750.50 | -11.9% | +14.3% | - | |
| Jan 5, 2026 | LLY Eli Lilly & Co | Lilly Endowment Inc | - | Sell | 1,390 | $1,085.01 | $1,508,165.29 | - | -11.0% | - | |
| Jan 5, 2026 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 9,070 | $33.79 | $306,452.63 | -9.0% | -41.4% | - | |
| Jan 5, 2026 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 7,875 | $487.38 | $3,838,084.96 | -13.8% | +14.3% | - | |
| Jan 5, 2026 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 35,416 | $4.60 | $162,913.60 | -11.3% | -23.1% | - | |
| Jan 5, 2026 | INDV Indivior Pharmaceuticals, Inc. | Stejbach Mark | Director | Buy | 775 | $35.39 | $27,429.27 | +4.8% | -16.1% | - | |
| Jan 5, 2026 | INDV Indivior Pharmaceuticals, Inc. | Humphreys Keith | Director | Buy | 775 | $35.39 | $27,429.27 | +15.4% | -16.1% | - | |
| Jan 5, 2026 | UTHR United Therapeutics Corp | Benkowitz Michael47 | President And COO | Sell | 14,625 | $487.38 | $7,127,877.16 | -13.8% | +14.3% | - | |
| Jan 5, 2026 | INDV Indivior Pharmaceuticals, Inc. | Ninivaggi Daniel A | Director | Buy | 775 | $35.39 | $27,429.27 | +4.8% | -16.1% | - | |
| Jan 5, 2026 | INDV Indivior Pharmaceuticals, Inc. | Wheadon David E. | Director | Buy | 1,771 | $35.39 | $62,680.29 | +14.0% | -16.1% | - | |
| Jan 5, 2026 | INDV Indivior Pharmaceuticals, Inc. | Ryan Barbara | Director | Buy | 775 | $35.39 | $27,429.27 | +65.2% | -16.1% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.